Nathalia de Paula Doyle Maia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nathalia de Paula Doyle Maia has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Freitas Ganança
Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina, Departamento de Otorrinolaringologia e Cirurgia Cérvico-Facial, Disciplina de Otologia e Otoneurologia, São Paulo, SP, Brazil
4 shared publications - Karen de Carvalho Lopes
Universidade Federal de São Paulo, Department of Otolaryngology and Head and Neck Surgery, São Paulo, SP, Brazil
4 shared publications
Latest Publications
- Open Access
- 20 May 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 88 (Suppl 3) , S81-S88
Vestibular function assessment in sudden hearing loss
- 20 May 2022
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 88 (Suppl 3) , S81-S88
Open AccessVestibular function assessment in sudden hearing loss
- Open Access
- 1 August 2021
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 47 (4) , 747-752
Otorhinolaryngological adverse effects of urological drugs
To describe the otorhinolaryngological adverse effects of the main drugs used in urological practice. A review of the scientific literature was performed using a combination of specific descriptors (side effect, adverse effect, scopolamine, sildenafil, tadalafil, vardenafil, oxybutynin, tolterodine, spironolactone, furosemide, hydrochlorothiazide, doxazosin, alfuzosin, terazosin, prazosin, tamsulosin, desmopressin) contained in publications until April 2020. Manuscripts written in English, Portuguese, and Spanish were manually selected from the title and The main drugs used in Urology were divided into five groups to describe their possible adverse effects: alpha-blockers, anticholinergics, diuretics, hormones, and phosphodiesterase inhibitors. The main drugs used in Urology may cause several otorhinolaryngological adverse effects. Dizziness was most common, but dry mouth, rhinitis, nasal congestion, epistaxis, hearing loss, tinnitus, and rhinorrhea were also reported and varies among drug classes. Most of the drugs used in urological practice have otorhinolaryngological adverse effects. Dizziness was most common, but dry mouth, rhinitis, nasal congestion, epistaxis, hearing loss, tinnitus, and rhinorrhea were also reported. Therefore, doctors must be aware of these adverse effects to improve adherence to the treatment and to minimize damage to the health of patients.
- 1 August 2021
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 47 (4) , 747-752
Open AccessOtorhinolaryngological adverse effects of urological drugs
To describe the otorhinolaryngological adverse effects of the main drugs used in urological practice. A review of the scientific literature was performed using a combination of specific descriptors (side effect, adverse effect, scopolamine, sildenafil, tadalafil, vardenafil, oxybutynin, tolterodine, spironolactone, furosemide, hydrochlorothiazide, doxazosin, alfuzosin, terazosin, prazosin, tamsulosin, desmopressin) contained in publications until April 2020. Manuscripts written in English, Portuguese, and Spanish were manually selected from the title and The main drugs used in Urology were divided into five groups to describe their possible adverse effects: alpha-blockers, anticholinergics, diuretics, hormones, and phosphodiesterase inhibitors. The main drugs used in Urology may cause several otorhinolaryngological adverse effects. Dizziness was most common, but dry mouth, rhinitis, nasal congestion, epistaxis, hearing loss, tinnitus, and rhinorrhea were also reported and varies among drug classes. Most of the drugs used in urological practice have otorhinolaryngological adverse effects. Dizziness was most common, but dry mouth, rhinitis, nasal congestion, epistaxis, hearing loss, tinnitus, and rhinorrhea were also reported. Therefore, doctors must be aware of these adverse effects to improve adherence to the treatment and to minimize damage to the health of patients.
- 1 March 2020
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 86 (2) , 247-254
Vestibular evoked myogenic potentials in the prognosis of sudden hearing loss – a systematic review
- 1 March 2020
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology (Versão em Português)
- Vol. 86 (2) , 247-254
Vestibular evoked myogenic potentials in the prognosis of sudden hearing loss – a systematic review
- Open Access
- 2 November 2019
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 86 (2) , 247-254
Vestibular evoked myogenic potentials in the prognosis of sudden hearing loss ‒ a systematic review
- 2 November 2019
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 86 (2) , 247-254
Open AccessVestibular evoked myogenic potentials in the prognosis of sudden hearing loss ‒ a systematic review